title: Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver.
abstract: The protective effect of berberine against antioxidant, antilipid peroxidation in serum and liver tissue, and positive transcription elongation factor b (P-TEFb) expression in liver tissue of type 2 diabetic rats was investigated. Overnight fasted rats were intraperitoneally injected 35 mg/kg streptozotocin. Diabetic rats were admitted after 2 weeks and given a high-carbohydrate/high-fat diet to induce hyperlipidemias. From week 16, diabetic rats were treated with 75, 150, 300 mg/kg berberine, 100mg/kg fenofibrate or 4 mg/kg rosiglitazone for another 16 weeks. P-TEFb (composed of cyclin-dependent kinase 9 and cyclin T1) mRNA and protein expression in liver tissue were detected by real time PCR and immunohistochemistry, respectively. Berberine significantly up-regulated the declined cyclin-dependent kinase 9, cyclin T1 mRNA and protein expression in diabetic rat liver. Berberine obviously decreased malondialdehyde level and increased catalase, superoxide dismutase, glutathione peroxidase, and glutathione activities in liver tissue and serum of diabetic rats. These results suggest that the effects of berberine on up-regulation of P-TEFb expression, antioxidant and antilipid peroxidation may be related to its protective potential on diabetes.
authors.affiliation: Base for Drug Clinical Trial, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, PR China.
authors.forename: Ji-Yin
authors.initials: JY
authors.lastname: Zhou
authors.forename: Shi-Wen
authors.initials: SW
authors.lastname: Zhou
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D001599:Berberine / Q000494:pharmacology* / Q000627:therapeutic use; D039323:Coptis / Q000737:chemistry*; D056906:Cyclin T / Q000235:genetics / Q000378:metabolism; D042863:Cyclin-Dependent Kinase 9 / Q000235:genetics / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D004032:Diet; D004365:Drugs, Chinese Herbal / Q000494:pharmacology / Q000627:therapeutic use; D004798:Enzymes / Q000378:metabolism; D011345:Fenofibrate / Q000494:pharmacology; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology; D000960:Hypolipidemic Agents / Q000494:pharmacology; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000378:metabolism*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008517:Phytotherapy; D042925:Positive Transcriptional Elongation Factor B / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D027343:Rhizome; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology; D015854:Up-Regulation
chemical_list: D000975:Antioxidants; D056906:Cyclin T; D004365:Drugs, Chinese Herbal; D004798:Enzymes; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D012333:RNA, Messenger; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D001599:Berberine; D008315:Malondialdehyde; D042925:Positive Transcriptional Elongation Factor B; D042863:Cyclin-Dependent Kinase 9; D011345:Fenofibrate